Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OATD-02 in Advanced Solid Tumors
NCT05759923Phase 1Recruiting
- Sponsor
- Molecure
- Start
- Jan 2023
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OAT-1746 in colorectal cancer (CRC), ovarian cancer, pancreatic cancer (PC) and 1 more, sponsored by Molecure. Primary endpoints: Adverse Events at 6 months and Dose Limiting Toxicities at 6 months. Started Jan 2023; status: recruiting.
02
Drugs
OAT-1746
03
Conditions
colorectal cancer (CRC)ovarian cancerpancreatic cancer (PC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05759923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05759923.